Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Should pharmaceutical companies continue to do business in Russia, running ongoing clinical trials, starting new ones, or continuing to sell their products there?
Some argue that medicine and science must not get enmeshed in politics, staying above the fray to protect their independence and credibility. Other defenders of business-as-usual say the pharmaceutical industry deals in health and aids the vulnerable
To continue reading this article ...
or
Continue reading your article with a Medscape account
Join the Top Medical Resource for Physicians Today. Free Membership!
Director, Division of Medical Ethics, New York University Langone Medical Center and School of Medicine, New York, NY
Disclosure: Arthur L. Caplan, PhD, has disclosed the following relevant financial relationships: Served as a director, officer, partner, employee, advisor, consultant, or trustee for: Johnson & Johnson's Panel for Compassionate Drug Use (unpaid position) Serves as a contributing author and advisor for: Medscape
Comments
Commenting is limited to medical professionals. To comment please Log-in.
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
A Psychiatric Patient Confesses to Murder: Now What?
Abortion Care Teaching 'Inconsistent in UK Medical Schools'
COMMENTARY
Pharma Should Stop Doing Business in Russia, Says Ethicist
Arthur L. Caplan, PhD
DisclosuresMarch 11, 2022
Should pharmaceutical companies continue to do business in Russia, running ongoing clinical trials, starting new ones, or continuing to sell their products there?
Some argue that medicine and science must not get enmeshed in politics, staying above the fray to protect their independence and credibility. Other defenders of business-as-usual say the pharmaceutical industry deals in health and aids the vulnerable
Join the Top Medical Resource for Physicians Today. Free Membership!
Medscape Business of Medicine © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Arthur L. Caplan. Pharma Should Stop Doing Business in Russia, Says Ethicist - Medscape - Mar 11, 2022.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Arthur L. Caplan, PhD
Director, Division of Medical Ethics, New York University Langone Medical Center and School of Medicine, New York, NY
Disclosure: Arthur L. Caplan, PhD, has disclosed the following relevant financial relationships:
Served as a director, officer, partner, employee, advisor, consultant, or trustee for: Johnson & Johnson's Panel for Compassionate Drug Use (unpaid position)
Serves as a contributing author and advisor for: Medscape